[1] SONG J, YANG CM, YU JY, et al.Translational Research and Review Decision Strategy of TCM Compound Preparations Based on Ancient Classical Prescriptions[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2024, 40(3): 2-7. [2] The State Council, the People's Republic of China. Opinions on Promoting the Inheritance and Innovation of Traditional Chinese Medicine[EB/OL]. (2019-10-20)[2024-11-20]. https://www.gov.cn/gongbao/content/2019/content_5449644.htm. [3] NMPA. Implementation Opinions on Promoting the Inheritance and Innovation of Traditional Chinese Medicine(2020)[EB/OL]. (2020-12-21)[2024-11-20]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20201225163906151.html. [4] General Office of the State Council, the People's Republic of China. A Circular was Issued on Several Policy Measures to Accelerate the Development of TCM Characteristics[EB/OL]. (2021-01-22)[2024-12-20]. https://www.gov.cn/gongbao/content/2021/content_5588816.htm. [5] The State Council, the People's Republic of China. Implementation Opinions on Comprehensively Strengthening Drug Regulatory Capacity Building[EB/OL]. (2021-04-27)[2024-11-20].https://www.gov.cn/gongbao/content/2021/content_5609083. htm. [6] NMPA. Notice on Several Measures to Further Strengthen the Scientific Supervision of Chinese Medicine and Promote the Inheritance and Innovation of Chinese medicine[EB/OL]. (2023-01-03)[2024-11-20].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20230103172324162.html. [7] NMPA. Special Provisions on the Administration of Registration of Chinese Medicine[EB/OL]. (2023-02-10)[2024-11-20]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20230210173401120.html. [8] CDE, NMPA. Technical Guidelines for Pharmaceutical Research on New Drugs of Chinese Herbal Compound Preparations Based on Human Experience (Trial) [EB/OL]. (2023-10-16)[2024-11-20]. https://www.cde.org.cn/main/news/viewInfoCommon/f7840a316591e68be0a0d9-b5a4a66d72. [9] CDE, NMPA. Other Technical Guidelines for Pharmaceutical Research of Traditional Chinese Medicine Compound Preparations Derived from Ancient Classical Prescriptions (Trial)[EB/OL]. (2023-07-21)[2024-11-20]. https://www.cde.org.cn/main/news/viewInfoCommon/861799feb6f3be49dbc8a365a3eeff0a. [10] CDE, NMPA. Technical Guidelines for the Preparation and Research of Drugs for Clinical Trials of New Chinese Medicines (Trial) [EB/OL].(2023-07-21)[2024-11-20]. https://www.cde.org.cn/main/news/viewInfoCommon/c36e5f39426b9a402be39c89016ebe7c. [11] AN N, HAN L, CHEN PY.Reflections on Real World Research Under the Evidence System of "Three Combinations" Registration and Evaluation of New Traditional Chinese Medicine[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(14): 1359-1363. [12] SONG CM.Reflections on the Clinical Research Pathways and Clinical Research Plan of Chinese New Drug Under the "Three Combination" Review Evidence System[J]. The Chinese Journal of Clinical Pharmacologys(中药临床药理学杂志), 2023, 39(17): 2581-2584. [13] ZHU XQ, CHENG JL, LI B, et al.Exploratory Practice and Prospect of Collecting and Collating Human Experience in TCM Medical Instit-utions[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(16): 1571-1573. [14] YANG ZQ, GAO R, HU SY, et al.Expert Consensus on Human Use Experience Research of Traditional Chinese Medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2022, 47(18): 4829-4834. [15] GAO MJ.Investigation on the Application of Human Use Experience in Filing Traditional Chinese Medicine Preparations for Record[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志) , 2022, 31(5): 359-364 [16] NMPA. Chinese Medicine Registration Classification and Application Data Requirements[EB/OL]. (2020-09-27)[2024-10-28]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200928164311143.html. [17] CDE, NMPA.Technical Guidelines for Pharmaceutical Research at Different Stages of New Drug Research (Trial) [EB/OL]. [2020-11-04][2024-10-28].https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=ad541123febec819335192c366aca232. [18] GU J, SONG J, LI P, et al.Interpretation of Technical Guideline for Pharmaceutical Research at Various Stages of Modern Chinese Medicine(Trial Version)[J]. World Journal of Integrated Traditional and Western Medicine(世界中西医结合杂志), 2020, 15(12):2332-2335. [19] CDE, NMPA. Guiding Principles for Clinical Research and Development of New Drugs Based on Human Experience of Chinese Herbal Compound Preparations (Trial)[EB/OL]. (2022-04-29)[2024-10-28]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzI-dCODE=ab8a9785226f419b63e5b2ab02242073. [20] SHEN JY, TAN CY, et al.Study on the Content of Phenylethanoid Glycosides in Fructus Ligustrum Lucidi from Different Producing Areas in Various Harvest Periods[J]. China pharmacist(中国药师), 2022, 25(1): 130-135. [21] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume I(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press, 2020. [22] LIANG ZB, LIU L, CHAO Z.Investigation of Medicinal Bupleurum Resources and Current Situation of Chaihu Production[J]. Shizhen Medicine and Materia Medica Research(时珍国医国药), 2012, 23(8): 2011-2013. [23] CDE, NMPA. Technical Guidelines for Research on Pharmaceutical Changes in Listed Chinese Medicines (Trial) [EB/OL].(2021-04-02) [2024-11-20]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=4a660e62fb19037bc5d932c3d0315097. [24] NMPA. Announcement on the Application of Traditional Technology to Medical Institutions to Prepare Traditional Chinese Medicine Prepa-rations for the Implementation of Record Management[EB/OL]. (2018-02-09)[2024-11-20]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20180212143401381.html. [25] CDE, NMPA. Technical Guidelines for Stability Research of Traditional Chinese Medicine Preparations (Trial) [EB/OL]. (2024-02-27)[2024-11-20]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=e9f9dc16c487e217df4739e2c5ee83ea. [26] XIAO XH, YAN D, MA LN, et al.Introduction to the Modernization of Traditional Chinese Medicine in Recent Ten Years[J]. Modern Chinese Medicine(中国现代中药), 2012, 14(1): 7-12. [27] ZHUO JX, QIU ZW, ZHOU J, et al.Evaluation for Druggability of Traditional Chinese Medicine Preparations in Medical Institutions Based on Human Use Experience[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2022, 4(15): 4256-4260. [28] YANG CM, WANG JX.On the Quality of Chinese Medicine Compound Preparation from Design[J]. Chinese Journal of Pharmaceuticals(中国医药工业杂志), 2016, 47(9): 1211-1215. [29] CHEN X, YANG CM, CHEN H, et al.Research of Preparation Process of Chinese Materia Medica Compound Preparation Based on Characteristics of Chinese Materia Medica Compound Preparation[J]. Chinese Traditional and Herbal Drugs(中草药), 2021, 52(19): 5807-5813. [30] XIAO XH, WANG JB, YAN D.Research and Application of Biological Evaluation in Quality Standardization of Traditional Chinese Medicine[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology(世界科学技术-中医药现代化), 2014, 16(3): 514-518. |